BRAF V600E Mutation Present
4 clinical trials · Condition
◉ Watch BRAF V600E Mutation Present
| Record | Firm | Date |
|---|---|---|
| Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer (NCT04061980) | Providence Health & Services | 2020-10-30 |
| Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma (NCT03224767) | Alliance for Clinical Trials in Oncology | 2018-01-05 |
| Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (NCT02097225) | National Cancer Institute (NCI) | 2014-05-29 |
| Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery (NCT01940809) | National Cancer Institute (NCI) | 2013-08-28 |
Track BRAF V600E Mutation Present automatically
Every clearance here is in the API, with alerts when new ones post.